Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Mobility, an autonomous vehicle (AV) technology company, announced an alliance relationship to bring new data and insight ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Coeptis Therapeutics Holdings, Inc. (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited ...

In a report released today, Michael Yee from Jefferies downgraded CARGO Therapeutics, Inc. (CRGX – Research Report) to a Hold, with a price ...